Close Menu

NEW YORK – Adaptive Biotechnologies announced Wednesday after the close of the market the pricing of a public offering of common stock that is expected to bring in gross proceeds of around $240 million for the firm.

The offering consists of 8 million shares of common stock, including 6 million being sold by Adaptive and 2 million being sold by a shareholder, at a price of $40 per share. Adaptive has granted the underwriters a 30-day option to purchase up to 1.2 million additional shares at the offering price, less underwriting discounts and commissions.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Russia says its candidate SARS-CoV-2 vaccine has a very high efficacy rate in an initial analysis of clinical trial data, according to the Financial Times.

Wired reports on a microbial analysis of sketches drawn by Leonardo DaVinci.

A new survey explores coronavirus vaccine hesitancy among Black and Latino individuals, the Washington Post reports.

In Nucleic Acids Research this week: the Aging Atlas database, a database of human metagenome-related metadata, and more.

Sponsored by

Management of viral infections is critical to prevent severe morbidities and consequences in immune-suppressed transplant patients.

Sponsored by
Mission Bio

Recent work by many investigators has discovered that over the course of aging, hematopoietic stem cells (HSCs) commonly undergo clonal expansion.